Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial

• Published in: Critical care (London, England) England), 2019-04, Vol.23 (1), p.108-108, Article 108
• Main Authors: Poli, Elettra C, Alberio, Lorenzo, Bauer-Doerries, Anna, Marcucci, Carlo, Roumy, Aurélien, Kirsch, Matthias, De Stefano, Eleonora, Liaudet, Lucas, Schneider, Antoine G
• Format: Article
• Language: English
• Subjects: Adsorption; Adult; Aged; Aged, 80 and over; Anesthesia; Cardiac patients; Cardio-pulmonary bypass; Cardiopulmonary Bypass - adverse effects; Cardiopulmonary Bypass - methods; Chemokine CCL2 - analysis; Chemokine CCL2 - blood; Chronic illnesses; Clinical outcomes; Clinical trials; Coagulation factors; Coronary artery bypass; Critical care; Cytokines; Cytokines - adverse effects; Cytokines - blood; Cytokines - metabolism; CytoSorb; Endocarditis; Evidence-based medicine; Female; Haemoadsorption; Health aspects; Heart surgery; Hemofiltration - instrumentation; Hemofiltration - methods; Hemofiltration - standards; Humans; Inflammation; Intensive care; Interleukin-10 - analysis; Interleukin-10 - blood; Interleukin-1alpha - analysis; Interleukin-1alpha - blood; Interleukin-1beta - analysis; Interleukin-1beta - blood; Interleukin-2 - analysis; Interleukin-2 - blood; Interleukin-4 - analysis; Interleukin-4 - blood; Interleukin-5 - analysis; Interleukin-5 - blood; Interleukin-6 - analysis; Interleukin-6 - blood; Kidneys; Laboratories; Male; Metabolic Clearance Rate; Middle Aged; Patients; Pilot Projects; Postoperative Complications - prevention & control; Surgery; Tumor Necrosis Factor-alpha - analysis; Tumor Necrosis Factor-alpha - blood; Von Willebrand factor
• ISSN: 1364-8535; 1466-609X; 1364-8535; 1366-609X
• DOI: 10.1186/s13054-019-2399-4

Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory response mediated by various cytokines. This response can, in severe cases, lead to systemic hypotension and organ dysfunction. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb® (Cytosorbents, NJ, USA) is a recent device designed to remove cytokine from the blood using haemoadsorption (HA). This trial aims to evaluate the potential of CytoSorb® to decrease peri-operative cytokine levels in cardiac surgery. We have conducted a single-centre pilot randomized controlled trial in 30 patients undergoing elective cardiac surgery and deemed at risk of complications. Patients were randomly allocated to either standard of care (n = 15) or CytoSorb® HA (n = 15) during cardiopulmonary bypass (CPB). Our primary outcome was the difference between the two groups in cytokines levels (IL-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, TNF-α, IFN-γ, MCP-1) measured at anaesthesia induction, at the end of CPB, as well as 6 and 24 h post-CPB initiation. In a consecutive subgroup of patients (10 in HA group, 11 in control group), we performed cross-adsorber as well as serial measurements of coagulation factors' activity (antithrombin, von Willebrand factor, factor II, V, VIII, IX, XI, and XII). Both groups were similar in terms of baseline and peri-operative characteristics. CytoSorb® HA during CPB was not associated with an increased incidence of adverse event. The procedure did not result in significant coagulation factors' adsorption but only some signs of coagulation activation. However, the intervention was associated neither with a decrease in pro- or anti-inflammatory cytokine levels nor with any improvement in relevant clinical outcomes. CytoSorb® HA during CPB was not associated with a decrease in pro- or anti-inflammatory cytokines nor with an improvement in relevant clinical outcomes. The procedure was feasible and safe. Further studies should evaluate the efficacy of CytoSorb® HA in other clinical contexts. ClinicalTrials.gov NCT02775123 . Registered 17 May 2016.